Alexander Lobo brings 6+ years of experience in Investor Relations and specializes in developing cohesive and impactful messaging for private and public life science companies across all stages of development and commercialization. Through his career, Alex has worked with a number of specialty pharmaceuticals, oncology, dermatology and gene therapy clients. He believes in developing strong relationships with each client and strives to provide thorough and insightful commentary, analysis, and counsel tailored to each clients’ unique situation.
Prior to joining SternIR, Alex was an Assistant Vice President at The Ruth Group, a boutique Investor Relations agency catering to small and microcap life science and medtech companies, which he joined in 2016. During his tenure at TRG, Alex worked closely with his clients through the IPO process, complex data announcements, and FDA interactions. He has worked to raise the awareness of under followed companies, both amongst the street and the banking and sell side communities.
Previously, Alex was an Investor Relations Associate for Cardiff Oncology (previously Trovagene, Inc.) a clinical stage, oncology company developing a lead candidate for hematologic and solid tumor cancers. Alex began his foray into healthcare through several internships at Pfizer Inc. spanning in the company’s U.S. Government Relations, Corporate Media, Corporate Responsibility and Worldwide Policy groups.
Alex holds a Bachelor of Arts in Political Science, with a minor in Psychology from The Pennsylvania State University.
In his spare time, Alex enjoys exploring food as an artistic and cultural experience, engaging in political discourse and taking the road less traveled. He is an audio and technology enthusiast and is always looking to grow his vinyl collection or looking at the next big thing in tech.